Pfizer reports that Prevenar 13 Phase 3 study meets all primary, secondary objectives

21:03 EDT 28 Apr 2013 | News-Medical.net

Pfizer Inc. presented today the results from a Phase 3 study investigating immunogenicity, tolerability and safety of Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]) in adults 18 to 49 years of age.

Original Article: Pfizer reports that Prevenar 13 Phase 3 study meets all primary, secondary objectives

NEXT ARTICLE

More From BioPortfolio on "Pfizer reports that Prevenar 13 Phase 3 study meets all primary, secondary objectives"

Search BioPortfolio:
Advertisement

Relevant Topic

The Top 100 Pharmaceutical Companies
Latest News Clinical Trials Research Drugs Reports Corporate
Top 100 Pharmaceutical Companies 2012 (SCRIP 100 - http://www.scrip100.com/scrip100.html) Rank (2011 in Brackets) Company SEARCH FOR COMPANY IN BIOPORTFOLIO'S BIOCORPORATE DATABASE 2012 pharma sales...

Advertisement

Searches Linking to this Story